Cancer drug shows promise for rare gene mutation, but study halted early
NCT ID NCT05023655
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called tazemetostat in people with advanced solid tumors that have a specific gene change (ARID1A mutation). The drug works by blocking a protein that helps these tumors grow. The study aimed to see if the drug could shrink tumors or stop them from growing. It was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Prisma Health Cancer Institute
Greenville, South Carolina, 29605, United States